Naval Daver MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center.
Naval Daver, MD expresses uncertainty and discusses the need for personalized treatment strategies. He mentions starting with a metaphor about eggs and ice cream preferences. They highlight the lack of data on triple therapy and the importance of considering individual differences.
The talk shifts to triple drug combinations and the complexity of treatment regimens. Naval Daver, MD emphasizes the need for optimized combinations and the challenges of dosing. He delves into different genetic mutations and their impact on treatment outcomes.
The discussion covers FLT3, IDH, and TP53 mutations, with a focus on ongoing studies to evaluate treatment efficacy. Naval Daver, MD addresses the complexities of treating older and unfit patients and mentions upcoming studies that could change AML treatment approaches.